The 2023 Annual Meeting will cover various aspects that will be important in future performance of clinical trials aiming at drug registration. It will cover the challenges related to population diversity, the practical aspects of decentralised trials, the difficulties faced in their early career by those involved in clinical trials, and will dwell on some regulatory topics.
- How to best ensure the relevant population diversity aspects in clinical trial for regulatory purposes
- Awareness on the various aspect of performing clinical trials in a de-centrale mode
- Which aspects are important to know for those in their early career related to clinical trials for registration purpose
The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.